PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: AstraZeneca
MedImmune Bets Its Fate on “Biobetters”
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market.
MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Europe: Resisting the Anticompetitive Crusade
It’s been another rocky few weeks for pharma in Europe. Particularly for big brand name companies. But necessity is proving the mother of invention, says Pharm Exec’s Brussels correspondent, Reflector.
AstraZeneca suffered a serious setback at the start of July when the European General Court ruled that it had illegally prevented generic competition. The case dates [...]
Posted in Strategy Also tagged Belgium, Commission, Competition law, European Commission, European Union, Generic drug, Pharmaceutical drug Leave a comment
AZ Celebrates Crestor Patent Win
The US District Court in Delaware upheld AstraZeneca’s patent for its blockbuster statin Crestor (rosuvastatin), ending a dispute that could have crippled the drugmaker’s billion-dollar cash cow.
Crestor’s patent is not scheduled to expire until 2016. However, a group of generics firms had claimed that a substance patent (314) protecting one of the active ingredients in [...]
Pharma Digital Smarts Quantified in IQ Index
Pfizer’s Viagra and AstraZeneca’s (AZ) Nexium took the top two slots on a new Digital IQ Index measuring the digital competence of 51 pharma brands across eight therapeutic categories. The ranking, created by think tank L2 in partnership with media agency PHD Network, evaluated brands’ digital presence across four criteria: platform (including site effectiveness and [...]
Two 'Most Promising' New Drugs Face Setbacks in US